• Summary

    Cancer doesn't merely represent health issue; the society by the long-term vision loses human resources and governmental budget for treatment process. The disease doesn't affect definite age or a specific social class; but it does extend to every family. Galectins are protein family with carbohydrate recognition domain and involved in many cellular functions. There are many labs worldwide have found a role of several galectins in cancer progression and metastasis. Our research team has found that eight members of the cancer-related galectins are dysregulated in Acute Myeloid Leukemia (AML). Interestingly, we have found that galectin-12 has clinical impact, as its upregulation is significantly associated with good prognosis in AML patients. Of note, more than 40% of these patients have upregulated galectin-9 which could be a future potential target with binding protein Tim3 for immunotherapy. This year, in cooperation with the German Cancer Research Center-Heidelberg and university of Bergen, Norway; we found that galectin-4 expression in cancer cells render them interactive with red blood cells. Many other studies from independent research groups found that galectin-4 and -8 are upregulated in the blood of metastatic cases of breast and lung cancers. More studies have shown increased level of galectin-1, -3, -4, and 8 in breast, liver, and lung. Therefore, we are submitting this proposal to study the feasibility of using galectins as prognostic markers.

  • Achievements


  • List of Publications from the Project


  • Partners

  • Project Members

  • Project Leaders

  • Project PI

    Reham Helwa

  • Faculty

    Faculty of Science

  • Research Group

  • Funding Agency

    STDF / STIFA

  • Funding Program

    STDF Basic & Applied Research Grants (STDF-BARG)

  • Start Date

    2021-06-10

  • End Date

    2023-06-09

  • Project website